Archive

  • Understanding The Role of Molecular Targeted Therapeutic Drugs In Non Small Cell Lung Cancer NSCLC: A Narrative Review
  • 1Department of Oral and Maxillofacial Pathology and Oral Microbiology, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India-452016
    2Department of Prosthodontics and Crown & Bridge, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India-452016
    3Department of Public Health Dentistry, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India-452016.

Abstract

Worldwide the second most common cancer is lung cancer with tobacco as the main reason for the disease. Lung cancer is chiefly classified into small cell lung cancer and non-small cell lung cancer. Various genes that cause tumorigenesis in non-small cell lung cancer are linked to multiple pathways like ALK, MET, EGFR, and RET. Genomic profiling and mutational analysis in recent years have progressed the field of genetics of lung cancer substantially. In this present review, we converse about the various targeted therapeutic drugs and their advancement in treatment of non-small cell lung cancer (NSCLC). The present review scrutinize the existing documentation in the literature related to the targeted therapies of non-small cell lung cancer (NSCLC). English language articles were searched in various databases such as Pubmed, Scopus, Science direct and Google scholar. The keyword used for searching are “non-small cell lung cancer”, “Targeted therapy”, “Therapeutic drugs”.

Keywords

Non small cell lung cancer, Therapeutic drugs, Targeted therapy

Reference

  1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.
  3. Sun, S., Schiller, J. & Gazdar, A. Lung cancer in never smokers — a different disease. Nat Rev Cancer.2007; 7, 778–790.
  4. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortalityworldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386
  5. Smith CJ, Perfetti TA, Rumple MA, Rodgman A, Doolittle DJ. “IARC Group 2A Carcinogens” reported in cigarette mainstream smoke. Food Chem Toxicol. 2000;38(4):371-383
  6. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409
  7. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-550
  8. Halmos B. Molecular testing in lung cancer: where to draw the line. Arch Pathol Lab Med. 2018;142(7):787-789.
  9. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20(12):1479-1484.
  10. Lam SW, Cleton-Jansen AM, Cleven A, et al. Molecular analysis of gene fusions in bone and soft tissue tumors by anchored multiplex PCR-based targeted next-generation sequencing. J Mol Diagn. 2018;20(5):653-663
  11. Davies KD, Le AT, Sheren J, et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J Thorac Oncol. 2018;13(10):1474-1482.
  12. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
  13. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863-870.
  14. Vendrell JA, Taviaux S, Beganton B, et al. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 2017;7(1):12510.
  15. Trombetta D, Sparaneo A, Fabrizio FP, Muscarella LA. Liquid biopsy and NSCLC. Lung Cancer Manag. 2016;5(2):91-104
  16. Marchio C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417-1427.
  17. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018;13(3):323-358
  18. Tsao AS, Scagliotti GV, Bunn PA Jr, et al. Scientific advances in lung cancer 2015. J Thorac Oncol. 2016;11(5):613-638.
  19. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32S-40S.
  20. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37.
  21. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:3908-14.
  22. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. fKRASN Engl J Med 2009;361:958-67
  23. Mendelsohn J, Masui H, Goldenberg A. Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway.
  24. Trans Assoc Am Physicians. 1987;100:173-178.
  25. Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harb Perspect Biol. 2014;6(4):a020768
  26. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339- 346
  27. Tsao AS, TangXM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR genemutation in non-small cell lung cancer. J Thorac Oncol. 2006;1(3):231-239
  28. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-181
  29. Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer. Lancet Oncol. 2006;7(6):499-507
  30. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13(5):539-548.
  31. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334.
  32. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-222.
  33. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3 Pt 1):839-844
  34. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17(6):1616-1622.
  35. Kobayashi S, Boggon TJ, DayaramT, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-792
  36. Park K, Janne PA, Yu C. 412OA global phase II study of olmutinib (HM61713) in patients with T790M-positive NSCLC after failure of first-line EGFR-TKI. Ann Oncol. 2017;28:mdx671.
  37. Wang H, Zhang L, Hu P, et al. Penetration of the blood–brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. Lung Cancer. 2018;122:1-6.
  38. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700-1709
  39. Kim D-W, Tan DSW, Aix SP, et al. Preliminary phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). J Clin Oncol. 2018;36:9094.
  40. Husain H, Martins RG, Goldberg SB. 1358PFirst-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLCafter progression on a first-line EGFRTKI. Ann Oncol. 2017;28;mdx380.
  41. Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36(26):2702-2709.
  42. Pulford K, Lamant L, Espinos E, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004;61(23):2939-2953.
  43. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281-1284.
  44. Soda M, Choi YL, EnomotoM, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-566.
  45. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015;21(10):2227-2235.
  46. Christensen JG, Zou HY, ArangoME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12 Pt1):3314-3322.
  47. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALK-positive non-small cell lung cancer. J Thorac Oncol. 2013;8(12):1570-1573.
  48. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.
  49. Wang Y, Yang N, Zhang Y, et al. Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by brigatinib and cetuximab combination therapy. J Thorac Oncol. 2020;15(8):1369- 1375.
  50. Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490-2498
  51. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029
  52. Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistantmutations. J Med Chem. 2014;57(11):4720-4744.
  53. Baglivo S, Ricciuti B, Ludovini V, et al. Dramatic response to lorlatinib in a heavily pretreated lung adenocarcinoma patient harboring G1202R mutation and a synchronous novel R1192P ALK point mutation. J Thorac Oncol. 2018;13(8):e145-e147
  54. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37-52.
  55. Facchinetti F,Rossi G, Bria E, et al.Oncogene addiction in nonsmall cell lung cancer: focus on ROS1 inhibition. Cancer Treat Rev. 2017;55:83-95.
  56. Birchmeier C, Sharma S, WiglerM. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A. 1987;84(24):9270-9274.
  57. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190-1203
  58. ShawAT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963-1971
  59. Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):261-270.
  60. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046-2051.
  61. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19(16):4532- 4540.
  62. Dankner M, Rose A, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183-3199.
  63. Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets. 2013;17(5):507-531.
  64. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: metaanalyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24(9):2371-2376
  65. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006
  66. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16(4-5):441-467
  67. Michels S, Scheel AH, Scheffler M, et al. Clinicopathological characteristics of RET rearranged lung cancer in European patients. J Thorac Oncol. 2016;11(1):122-127.
  68. Ferrara R, Auger N, Auclin E, Besse B. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. J Thorac Oncol. 2018;13(1):27-45.
  69. LiuD, Zhong M, ZhanD, Zhang Y, Liu S.Roles of theHGF/Met signaling in head and neck squamous cell carcinoma: focus on tumor immunity (Review). Oncol Rep. 2020;44(6):2337-2344.
  70. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006;66(1):283-289
  71. Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47-51.
  72. Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14- mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944-957
  73. Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015;5(10):1049-1057.
  74. 7Marcus L, Donoghue M, Aungst S, et al. FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors. Clin Cancer Res. 2021;27(4):928-932
  75. Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. Cancer. 2017;123(21):4099-4105.
  76. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10(1):25-38.
  77. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-1380
  78. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65(5):1642-1646.
  79. Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol. 2020;38(15):9504.
  80. Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532-2537
  81. Herbst RS, Fidler IJ. Angiogenesis and lung cancer: potential for therapy. Clin Cancer Res. 2000;6(12):4604-4606. 
  82. Meert AP, PaesmansM,Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2002;87(7):694-701.
  83. Ferrara N, GerberHP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676
  84. Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593-4599
  85. SandlerA,Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550
  86. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J ClinOncol. 2010;28(5):780-787.
  87. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for secondline treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673
  88. Hall RD, Le TM, Haggstrom DE, Gentzler RD. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015;4(5):515-523.
  89. Paz-Ares L, Hirsh V, Zhang L, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial: a phase III, multicenter, placebocontrolled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol. 2015;10(12):1745-1753.
  90. Baggstrom MQ, Socinski MA, Wang XF, et al. Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance). J Thorac Oncol. 2017;12(5):843-849.
  91. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11(7):619-626.
  92. Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105.

Photo
Himanshu Singh
Corresponding author

Department of Oral and Maxillofacial Pathology and Oral Microbiology, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India-452016

Photo
Arunee Garg
Co-author

Department of Oral and Maxillofacial Pathology and Oral Microbiology, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India-452016

Photo
Nency Parihar
Co-author

Department of Prosthodontics and Crown & Bridge, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India-452016

Photo
Vedant Patel
Co-author

Department of Prosthodontics and Crown & Bridge, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India-452016

Photo
Ranjan Mani Tripathi
Co-author

Department of Public Health Dentistry, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India-452016

Himanshu Singh*, Arunee Garg, Nency Parihar, Vedant Patel, Ranjan Mani Tripathi, Understanding The Role of Molecular Targeted Therapeutic Drugs In Non-Small Cell Lung Cancer (NSCLC): A Narrative Review, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 9, 77-87. https://doi.org/10.5281/zenodo.8325641

More related articles
A Complete Assessment On Herbal Nanogels...
Akshita Deb, Deeparani Urolagin, Ansari Aashif Raza Mohd Imtiyaz,...
An Overview Of Muscular Dystrophy...
Yenkathala Shivani, Grishma Krishnan, Ishu, Aashutosh Sinwal, Ama...
Formulation And Evaluation Of Herbal Lip Gloss By Using Dacus Carota And Crocus ...
Deepa Chandrawanshi, Komal Harinkhede, Khushi Turkar, Khushiya Patle, Harsha Katre, Alka Bisen, ...
An Interventional Study On Hemodialysis Patient And Impact Of Patient Counseling...
Basheera. V, Rahna Rasheed, Remeeza Jabbar, Rinsa. A, ...
Related Articles
New Developments In The Photodynamic Therapy For Hypoxia Tumor By Using Oxphos-T...
Mayuri N. Jagtap, Avinash B. Darekar, Vedant Uday Dhoke, ...
A Review On : Development And Evaluation Of Efficacy Of Herbal Mosquito Repellan...
Priyanka D. Gaikwad, Apeksha N. Chavhat, Pratik P. Wani, Meghana Rayjade, ...
Formulation and Evaluation of Sustained Release Tablet of an AntiDiabetic Drug V...
Mayur Gokul Jayswal, Vasudev Sharma, Adnan Siddiqui, Raza Khan, Shaikh Aaqueeb Ahmed, Afsar Shaikh, ...
A Complete Assessment On Herbal Nanogels...
Akshita Deb, Deeparani Urolagin, Ansari Aashif Raza Mohd Imtiyaz, Samir Panda, Arundhati Kashyap, ...
More related articles
A Complete Assessment On Herbal Nanogels...
Akshita Deb, Deeparani Urolagin, Ansari Aashif Raza Mohd Imtiyaz, Samir Panda, Arundhati Kashyap, ...
An Overview Of Muscular Dystrophy...
Yenkathala Shivani, Grishma Krishnan, Ishu, Aashutosh Sinwal, Aman Saini, Pooja Brahambhatt, ...
A Complete Assessment On Herbal Nanogels...
Akshita Deb, Deeparani Urolagin, Ansari Aashif Raza Mohd Imtiyaz, Samir Panda, Arundhati Kashyap, ...
An Overview Of Muscular Dystrophy...
Yenkathala Shivani, Grishma Krishnan, Ishu, Aashutosh Sinwal, Aman Saini, Pooja Brahambhatt, ...